Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia
Paris (France) and Cambridge (Massachusetts, États-Unis), July 15, 2025 – 07:00am – Biophytis SA, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, today announced a strategic partnership with Lynx Analytics, a pioneer in artificial intelligence solutions for life sciences. The collaboration aims to accelerate the discovery and development of novel small molecule drugs for the treatment of sarcopenia, a debilitating condition characterized by progressive loss of muscle mass and strength in old adults.
Sarcopenia represents a significant and growing unmet medical need, with no FDA-approved therapies currently available. By leveraging Lynx’s advanced AI expertise, Biophytis will be able to rapidly identify and optimize small molecules that can be efficient in muscle preservation and regeneration. This partnership will unite Biophytis’ expertise in age-related disease biology with Lynx’s cutting-edge computational technologies, enabling a more efficient and targeted approach to drug development.
The partnership will focus on:
• Utilizing AI algorithms to mine biomedical data.
• Accelerating preclinical validation and candidate selection through in silico modeling and advanced analytics.
• Building a robust pipeline of drug candidates with the potential to restore muscle function and improve quality of life for individuals affected by sarcopenia.
“Our collaboration with Lynx Analytics marks a transformative step in our mission to address sarcopenia at its root cause,” said Stanislas Veillet, CEO of Biophytis. “By integrating artificial intelligence into our drug discovery process, we aim to significantly reduce the time and cost required to bring effective therapies to patients in need.”